Genolution's subsidiary Bianble Biotech has registered a patent for a plasma skincare device incorporating ozone-reduction technology.


Bianble Biotech Registers Patent for Ozone-Reducing Plasma Skincare Device View original image

According to Bianble Biotech on November 18, the patent covers technology that draws in and purifies ozone inside the device before it can spread outside during the operation of a personal plasma beauty device. Bianble Biotech developed a proprietary intake structure that draws outside air into the device the moment it comes into contact with the skin, directing the ozone to a purification filter for removal.


The technology is already being used in products from Bianble Biotech's premium beauty brand, "Angbeul Ppeuritti." According to the company's test data, the product's ozone emission concentration was measured at 0.000219 ppm. This is only about 0.44% of the U.S. Food and Drug Administration's (FDA) maximum allowable ozone emission level of 0.05 ppm.


Bianble Biotech plans to strengthen its brand presence in the existing business-to-consumer (B2C) home beauty market and expand into the business-to-business (B2B) market, targeting professional skincare institutions and other organizations. Having secured an original patent for a skin treatment device, the company also plans to gradually assess the possibility of entering the medical device market by further developing related technologies and products.



A Bianble Biotech representative said, "We will support the subsidiary in establishing a foundation for growth by strengthening product competitiveness and expanding distribution channels, and contribute to diversifying Genolution's business portfolio."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing